Drugs · acquisition-cost intelligence
Adderall
Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate, Amphetamine Sulfate· ingredient dextroamphetamineCentrally acting sympathomimetics· AMPHETAMINE ASPARTATE 1.25 mg/1; AMPHETAMINE SULFATE 1.25 mg/1; AMPHETAMINE ASPARTATE 1.875 mg/1; AMPHETAMINE SULFATE 1.875 mg/1; AMPHETAMINE ASPARTATE 2.5 mg/1; AMPHETAMINE SULFATE 2.5 mg/1; AMPHETAMINE ASPARTATE 3.125 mg/1; AMPHETAMINE SULFATE 3.125 mg/1
What this is. Acquisition-cost intelligence for pharmacy & clinic buyers — the historical trend, generic-equivalent costs, and Part D posture. NADAC is a pharmacy acquisition cost (the national average pharmacies pay), not a retail or cash price — for consumer cash prices use GoodRx/your plan.
Acquisition benchmark · NADAC per EA
$0.25990
NADAC — pharmacy acquisition cost, not a retail/cash price
Acquisition-cost history
Weekly NADAC per EA — the trend nobody else shows. 7 weeks.
2025-12-172026-05-20
Same-ingredient options by acquisition cost
Other dextroamphetamine products, cheapest acquisition cost first. Per EA — confirm strength/form equivalence before switching.
| Product | NADAC / EA | vs this |
|---|---|---|
| Zenzedi | $0.42657 | +$0.16670 |
| Adderall XR | $0.54992 | +$0.29000 |
| PROCENTRA | $1.11 | +$0.85190 |
| DEXEDRINE SPANSULE | $1.34 | +$1.08 |
| Mixed Salts of a Single-Entity Amphetamine Product | $8.51 | +$8.25 |
| XELSTRYM | $16.26 | +$16.00 |
Medicare Part D coverage · CY2026
On 326 plan formularies · typical tier 3
Prior auth 20% · Step therapy 0% · Quantity limit 80% of formularies
Sources: CMS NADAC (pharmacy acquisition cost), FDA NDC + RxNorm (identity), RxClass (therapeutic class), CMS Medicare Part D formulary (coverage). Observed reference data for professional buyers — not a retail/cash price, not pricing or medical advice. Verify before purchasing or substituting.